ProMIS Neurosciences Inc. (PMN) is a pre-revenue clinical-stage biopharmaceutical company with zero product revenue since inception. Under a liquidation lens, recovery to equity is marginally positive at the March 31, 2026 balance sheet date, primarily because the January 2026 PIPE transaction injected $70.1 million in net cash proceeds, bringing the cash position to $63.8 million against total liabilities of only $6.7 million. Applying a 100% recovery haircut to cash and near-cash assets, liquidation proceeds on the asset side approximate $63.8 million in cash plus $1.8 million in prepaid and other current assets (discounted to roughly $1.5 million at ~85% blended recovery), and $1.8 million in noncurrent prepaid (likely zero recovery on liquidation given CRO/clinical deposit nature). Total liabilities at face value are $6.7 million, of which current liabilities ($6.6 million: $1.7 million accounts payable, $4.9 million accrued liabilities, $0.1 million professional fees accrual, $0.1 million other accruals) dominate. Noncurrent liabilities are limited to $79K in deferred compensation classified noncurrent. On a quick-math basis, liquidation value to equity is approximately $63.8 million cash minus $6.7 million liabilities, or roughly $57 million, consistent with the MFFAIS CLV/LLV/OLV estimate of $57.2 million. This positive recovery posture is entirely a function of the large cash raise; the underlying asset base carries no tangible or intangible property of consequence — PP&E is de minimis and intangibles (patents, pipeline) are carried at zero under the company's expensing policy and would receive a zero haircut in any event. Accumulated deficit stands at $138.7 million as of March 31, 2026. Operating cash burn was $12.4 million for Q1 2026, driven by $6.3 million in PMN310 Phase 1b PRECISE-AD trial costs and $1.1 million in employee costs, versus $4.9 million in the prior-year comparable quarter. At the Q1 2026 run rate, the current cash balance provides roughly 5 quarters of runway before the $57 million net liquidation value erodes to zero. Management guides runway through 2027 under current operating plan assumptions. The liability stack contains no debt, no operating lease obligations separately tagged, and no pension obligations. The only non-current liability of note is the $79K DSU liability. Contingent milestone and royalty obligations under UBC and other license agreements are disclosed in MD&A but not accrued; the filing states no events have occurred requiring accrual. Filing discusses the $70.1 million net PIPE proceeds and associated warrant/pre-funded warrant issuance in MD&A but does not separately XBRL-tag the gross proceeds, placement agent fees, or individual equity component allocations — those items are referenced only in narrative.
▼ Community Notes